Phase 2b, Multicenter Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer.

Trial Profile

Phase 2b, Multicenter Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs BC 819 (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Sponsors BioCancell Therapeutics
  • Most Recent Events

    • 09 Feb 2018 Results presented in a BioCancell Therapeutics Media Release.
    • 09 Feb 2018 According to a BioCancell Therapeutics media release, final analysis of this trial were presented at the 2018 ASCO Genitourinary Cancers Symposium.
    • 15 Nov 2017 According to a BioCancell Therapeutics media release, Patients are being followed for up to 2 years, and the median follow-up at the time of the analysis is approximately 18 months.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top